Researchers from the Banner Alzheimer’s Institute in Phoenix introduced Novartis Pharmaceuticals Corporation as their partner in the upcoming Alzheimer’s Prevention Initiative ApoE4 trial.
Banner will work with the Swiss pharmaceutical company to test experimental therapies in people who carry two copies of the ApoE4 allele, the major genetic risk factor for late-onset Alzheimer’s disease. The study complements the API ADAD trial, which will test the anti-A? antibody crenezumab in otherwise healthy people who carry an autosomal-dominant AD mutation and typically begin to show signs of the disease by age 50.
”We are excited about the chance to evaluate promising preclinical AD treatments in those at risk for developing AD at older ages,” said Eric Reiman, who leads API together with Pierre Tariot and Jessica Langbaum at Banner. ”We previously argued that now is the time to launch a new era in Alzheimer’s prevention research—one in which we could efficiently test the range of preclinical AD treatments and find those that work,” he said.